Innovative Solutions and Support, Inc. Price & Performance (ISSC)

Aldeyra Therapeutics is under investigation by shareholder law firms following a dramatic 75% drop in its stock price. The sell-off was triggered after the FDA rejected its dry eye drug, citing insufficient evidence of efficacy and methodological flaws in clinical trials. Investors are now weighing legal action as confidence erodes.1

The Sabin Vaccine Institute has begun a Phase II clinical trial for its Marburg virus vaccine candidate, enrolling 200 adults across multiple U.S. states. The double-blind, placebo-controlled study will focus on safety and immune response, with participants monitored over a year. The initiative addresses an urgent need for filovirus countermeasures.2

Meta’s content moderators are experiencing unprecedented stress, with reports of suicide attempts and increased dismissals at a new, secretive facility. Workers describe a harsh environment and enforced silence about their work, raising concerns about occupational health and transparency as the company faces ongoing scrutiny over its moderation practices.3